Why formally ending the pandemic will be a big headache; Sacklers agree to $6B Purdue bankruptcy settlement

The next chapter of our Covid response will center on unwinding the tangle of policies put in place to help the country address the virus. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Why formally ending the pandemic is going to be a huge headache for the entire health care system By Rachel Cohrs Mike Reddy for STAT The next chapter of our Covid response will center on unwinding the tangle of policies put in place to help the country address the virus. Read More Sacklers agree to $6 billion Purdue bankruptcy settlement over opioid crisis By Ed Silverman Douglas Healey/AP The Sackler family members who own Purdue Pharma have agreed to a $6 billion settlement over the company's role in the opioid crisis. Read More STAT+: Civica Rx has an ambitious plan to make low-cost insulin for all Americans. But can it work? By Ed Silverman Alissa Ambrose/STAT Civica Rx announced plans to sell its own versions of three widely prescribed insulin brands. Will it work? Read More Sponsor content by STAT Events The STAT Breakthrough Science Summit On March 31, take an inside look at the technologies and procedures set to redefine medicine, and change patient care in the years to come. You'll hear from the CEOs, scientists, entrepreneurs at the forefront of these efforts. Get your pass now, and use your STAT+ subscriber login to unlock a 20% discount. STAT+: With Aduhelm in limbo, Biogen starts laying off employees By Adam Feuerstein and Damian Garde Steven Senn/AP Biogen has said it hopes to save $500 million a year in the process, triggered in part by the disappointing launch of its Alzheimer's drug. Read More STAT+: Even as it struggles, startup insurer Bright Health deepens its ties to Cigna By Bob Herman Adobe Bright Health is hemorrhaging money, raising questions not only about its future but also about its increasingly close relationship with Cigna Read More Listen: Biden's plans for Covid pills, the latest vaccine data, & fighting about CRISPR By Damian Garde and Meg Tirrell and Adam Feuerstein This week, physician and researcher Kavita Patel joins us to explain why President Biden's plans for Covid-19 might not be so simple. Read More Opinion: Turning to social media to get affordable insulin: a clear sign of a broken health care system By Alina Bills Adobe Some people with diabetes must turn to an underground market for affordable insulin and other supplies. They shouldn't have to do that. Read More Opinion: Inappropriate march-in actions would jeopardize public-private partnerships that make lifesaving medicines possible By Mark Reisenauer Adobe Using Bayh-Dole march-in rights to lower a drug's price would set a troubling precedent and jeopardize new drug discovery and development. Read More Thursday, March 3, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser